Brief: Virpax Pharmaceuticals Says Liposomal Formulation Developed To Provide Both Immediate And Sustained Pain Relief
30/04/2024 12:37
April 30 (Reuters) - Virpax Pharmaceuticals Inc
VRPX.O :
* VIRPAX ANNOUNCES RESULTS OF MAXIMUM TOLERATED DOSE STUDY
FOR
PROBUDUR™
* VIRPAX PHARMACEUTICALS INC - LIPOSOMAL FORMULATION
DEVELOPED TO
PROVIDE BOTH IMMEDIATE AND SUSTAINED PAIN RELIEF
Source text for Eikon: ID:nBw3BZnJ7a
Further company coverage: VRPX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Virpax Pharmaceuticals
See all newsVirpax Pharma plunges as Nasdaq delisting looms
Brief: Virpax Pharmaceuticals Files For Offering On Best Efforts Basis Up To 2.4 Million Shares Of Common Stock
Brief: Virpax receives positive Probudur™ results for dose range study
Brief: Virpax Looking To Use Met To Develop Intranasal Covid Vaccine
Brief: Virpax Confirms Positive Results With Us Army With Probudur™ For Combat Care Study